Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Enterprise Value (2016 - 2026)

Soleno Therapeutics (SLNO) has disclosed Enterprise Value for 9 consecutive years, with -$305.5 million as the latest value for Q4 2025.

  • For Q4 2025, Enterprise Value changed N/A year-over-year to -$305.5 million; the TTM value through Dec 2025 reached -$305.5 million, changed N/A, while the annual FY2025 figure was -$305.5 million, N/A changed from the prior year.
  • Enterprise Value hit -$305.5 million in Q4 2025 for Soleno Therapeutics, up from -$499.0 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$286.8 million in Q2 2025 and bottomed at -$499.0 million in Q3 2025.